Roche Settles Perjeta Patent Suit on Organon, Henlius Biosimilar

Roche Holding AG subsidiaries have settled their patent suit over Shanghai Henlius Biotech Inc. and Organon & Co.'s biosimilar version of the blockbuster breast-cancer drug Perjeta, the companies said in a federal court filing.

The Swiss company’s Genentech Inc. and Hoffmann-La Roche Inc. units and the co-defendants agreed to dismiss all claims and counterclaims, closing the door on any chance to renew allegations, according to their proposed joint stipulation of dismissal filed Thursday in the US District Court for the District of New Jersey.

The filing provided no further details on the agreement.

The US Food and Drug Administration approved ...